ATE301201T1 - Für die gentherapie verwendbare plasmide - Google Patents

Für die gentherapie verwendbare plasmide

Info

Publication number
ATE301201T1
ATE301201T1 AT94919290T AT94919290T ATE301201T1 AT E301201 T1 ATE301201 T1 AT E301201T1 AT 94919290 T AT94919290 T AT 94919290T AT 94919290 T AT94919290 T AT 94919290T AT E301201 T1 ATE301201 T1 AT E301201T1
Authority
AT
Austria
Prior art keywords
pct
gene therapy
date dec
sec
plasmids usable
Prior art date
Application number
AT94919290T
Other languages
English (en)
Inventor
Gary J Nabel
Elizabeth G Nabel
Denise Lew
Magda Marquet
Original Assignee
Vical Inc
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc, Univ Michigan filed Critical Vical Inc
Application granted granted Critical
Publication of ATE301201T1 publication Critical patent/ATE301201T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
AT94919290T 1993-06-07 1994-05-27 Für die gentherapie verwendbare plasmide ATE301201T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7434493A 1993-06-07 1993-06-07
PCT/US1994/006069 WO1994029469A2 (en) 1993-06-07 1994-05-27 Plasmids suitable for gene therapy

Publications (1)

Publication Number Publication Date
ATE301201T1 true ATE301201T1 (de) 2005-08-15

Family

ID=22119050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94919290T ATE301201T1 (de) 1993-06-07 1994-05-27 Für die gentherapie verwendbare plasmide

Country Status (7)

Country Link
US (1) US5910488A (de)
EP (1) EP0702722B1 (de)
JP (1) JP3626187B2 (de)
AT (1) ATE301201T1 (de)
CA (1) CA2164088C (de)
DE (1) DE69434447T2 (de)
WO (1) WO1994029469A2 (de)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US6936464B1 (en) 1992-10-02 2005-08-30 Cancer Research Technology Limited Immune responses to fusion proteins
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
WO1996006938A1 (de) * 1994-08-26 1996-03-07 Hoechst Aktiengesellschaft Gentherapeutische behandlung von gefässerkrankungen durch einen zellspezifischen, zellzyklusabhängigen wirkstoff
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
ES2264136T3 (es) * 1995-02-21 2006-12-16 Cantab Pharmaceuticals Research Limited Preparaciones virales, vectores, inmunogenos y sus vacunas.
US5824485A (en) * 1995-04-24 1998-10-20 Chromaxome Corporation Methods for generating and screening novel metabolic pathways
US6265387B1 (en) * 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US7507722B1 (en) * 1999-11-05 2009-03-24 Roche Madison Inc. Intravascular delivery of nucleic acid
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
EP0877752B1 (de) 1996-01-23 2003-05-21 The Board Of Trustees Of The Leland Stanford Junior University Verfahren zur suche nach transdominanten effektorpeptiden und rna-molekülen
US5783431A (en) * 1996-04-24 1998-07-21 Chromaxome Corporation Methods for generating and screening novel metabolic pathways
US6242211B1 (en) 1996-04-24 2001-06-05 Terragen Discovery, Inc. Methods for generating and screening novel metabolic pathways
EP0803573A1 (de) * 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronische Expressionskonstrukt mit Cytokinen für multivalente Impstoffe
EP0805207A1 (de) * 1996-05-02 1997-11-05 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronische Expressionsplasmid für Tumorabstossungen
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
JP2001512973A (ja) * 1997-02-24 2001-08-28 ヘキスト・マリオン・ルセル・インコーポレイテッド β−アミロイドのプロセシングの改良されたアッセイ
EP1019082B2 (de) 1997-10-02 2008-06-04 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Verwendung eines kolonie-stimulierenden faktors (csf) zum verstärken des kollateralen wachstums von kollateralen arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
JP2001523480A (ja) * 1997-11-20 2001-11-27 バイカル インコーポレイテッド サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US9585916B2 (en) 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
CA2266805C (en) 1998-03-27 2015-04-28 An-Go-Gen Inc. Cell-based gene therapy in the treatment of pulmonary disorders
US6482406B1 (en) 1999-03-26 2002-11-19 Duncan J. Stewart Cell-based gene therapy for the pulmonary system
US6592623B1 (en) 1999-08-31 2003-07-15 Virginia Commonwealth University Intellectual Property Foundation Engineered muscle
DE60012711T2 (de) * 1999-03-26 2005-08-18 Vical, Inc., San Diego Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
WO2000061184A2 (en) * 1999-04-08 2000-10-19 Glenn Gregory M Dry formulation for transcutaneous immunization
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6541458B1 (en) * 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
ES2269199T3 (es) * 1999-11-05 2007-04-01 Mirus Bio Corporation Suministro intravascular de acido nucleico.
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
AU1954001A (en) * 1999-12-10 2001-06-18 Ariad Gene Therapeutics, Inc. Methods for high level expression of genes in primates
US7078388B2 (en) * 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
EP1278551A2 (de) * 2000-04-21 2003-01-29 Vical Incorporated Zusammensetzungen und verfahren zur (in vivo) verabreichung der auf polynukleotiden-basierenden therapeutika
US6645745B1 (en) 2000-05-30 2003-11-11 Epidauros Biotechnologie Ag Identification of a new member of the cytochrome P450 3A (CYP3A) gene family: CYP3AX
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
DE60143959D1 (de) 2000-08-25 2011-03-10 Basf Plant Science Gmbh En kodieren
WO2002018546A2 (en) 2000-09-01 2002-03-07 Virginia Commonwealth University Intellectual Property Foundation Plasma-derived-fibrin-based matrices and tissue
EP1366077B1 (de) 2000-09-15 2011-05-25 Coley Pharmaceutical GmbH Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten
US20030074679A1 (en) * 2000-12-12 2003-04-17 Schwartz Robert J. Administration of nucleic acid sequence to female animal to enhance growth in offspring
WO2002059142A2 (en) 2001-01-26 2002-08-01 Epidauros Biotechnologies Ag Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (mrp-1) and their use in diagnostic and therapeutic applications
EP1372708B1 (de) 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Impstoffe zur transkutanen immunisierung gegen reisediarrhö
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
WO2003015716A2 (en) * 2001-08-13 2003-02-27 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
US20030109037A1 (en) * 2001-09-24 2003-06-12 Reid Christopher Brian Methods for application of genetically-modified endogenous or exogenous stem/progenitor or their progeny for treatment of disease
US20080206202A1 (en) * 2001-09-24 2008-08-28 Christopher Reid Methods for application of endogenous or exogenous stem/progenitor or their progeny for treatment of disease
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
ATE459880T1 (de) 2002-04-17 2010-03-15 Deutsches Krebsforsch Verfahren zum screening einer substanz zur modulierung der wnt -signalkaskade.
SI1496944T1 (sl) * 2002-05-01 2009-02-28 Univ Florida Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov
US20060093589A1 (en) * 2004-02-19 2006-05-04 Warrington Kenneth H Vp2-modified raav vector compositions and uses therefor
CA2542171C (en) 2002-06-26 2015-12-15 Abbott Gmbh & Co. Kg Modulators and modulation of the interaction between rgm and neogenin
US6809191B2 (en) * 2002-07-03 2004-10-26 Vaxim, Inc. GM-CSF nucleic acid sequences
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
AU2003302724A1 (en) * 2002-08-13 2004-07-09 Mcivor, Scott, R. Methods of using vectors to treat metabolic disorders
AU2003260426A1 (en) 2002-08-16 2004-03-11 Glycotope Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
WO2004018512A2 (en) 2002-08-23 2004-03-04 Epidauros Biotechnologie Ag Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications
WO2004032713A2 (en) * 2002-10-04 2004-04-22 Nanomatrix, Inc. Sealants for skin and other tissues
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040136960A1 (en) * 2003-01-10 2004-07-15 Wolff Jon A. Devices and processes for distribution of genetic material to mammalian limb
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
DK1654353T3 (da) 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
ATE466106T1 (de) 2003-10-10 2010-05-15 Deutsches Krebsforsch Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
US7700737B2 (en) 2003-12-05 2010-04-20 Multimmune Gmbh Therapeutic and diagnostic anti-Hsp70 antibodies
CN1989244B (zh) 2004-02-09 2013-04-03 柏格丹由里 用于治疗cns病症的tgf-r信号传递抑制剂
US7504243B2 (en) 2004-03-19 2009-03-17 The United States Of America As Represented By The Department Of Health And Human Services Methods for the production of biliverdin
CA2568201C (en) 2004-05-24 2013-07-30 Universitat Zu Koln Identification of ergothioneine transporter and therapeutic uses thereof
EP1602926A1 (de) 2004-06-04 2005-12-07 University of Geneva Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
CN101094688B (zh) 2004-09-13 2013-05-01 建新公司 多聚构建体
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US8048446B2 (en) * 2005-05-10 2011-11-01 Drexel University Electrospun blends of natural and synthetic polymer fibers as tissue engineering scaffolds
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
LT2444424T (lt) 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
US20090068158A1 (en) * 2005-12-09 2009-03-12 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
CA2566267A1 (en) * 2005-12-09 2007-06-09 University Health Network Thymidylate kinase mutants and uses thereof
NZ569204A (en) 2005-12-21 2012-03-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
EP2514824A3 (de) 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Verfahren und Zusammensetzungen zum Behandeln und Erkennen von missgefaltetem SOD 1-herbeigeführte Erkrankungen
CA2655990A1 (en) 2006-06-22 2007-12-27 Tai June Yoo Restoration of hearing loss
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2008086556A1 (en) 2007-01-16 2008-07-24 The University Of Queensland Method of inducing an immune response
CN106890342B (zh) 2007-02-06 2022-09-23 俞泰俊 使用基因疗法治疗和预防神经变性疾病
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2008124768A1 (en) 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
UA100692C2 (ru) 2007-05-02 2013-01-25 Мериал Лимитед Днк-плазмиды, имеющие повышенную экспрессию и стабильность
EP2208737B1 (de) 2007-05-03 2017-07-05 Lysomab GmbH Komplementierte Faktor-H-abgeleitete Kurzkonsenswiederholung-Antikörperkonstrukte
US8765462B2 (en) 2007-05-04 2014-07-01 University Health Network IL-12 immunotherapy for cancer
WO2008148057A2 (en) 2007-05-23 2008-12-04 Vical Incorporated Cationic lipids compositions and methods for enhancing immune responses to vaccines
US20110217274A1 (en) 2007-05-29 2011-09-08 Reld Christopher B Methods for production and uses of multipotent ,pluripotent, differentiated and disease-resistant cell populations
WO2009095517A2 (es) 2008-01-29 2009-08-06 Proyecto De Biomedicina Cima, S.L. Métodos y composiciones capaces de provocar un silenciamiento post-transcripcional de la expresión génica de forma sinérgica
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009114942A1 (en) * 2008-03-20 2009-09-24 University Health Network Thymidylate kinase fusions and uses thereof
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
US9694055B2 (en) 2008-05-09 2017-07-04 Wake Forest University Health Sciences Renal tissue regeneration
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
MX2011003502A (es) 2008-10-01 2011-09-01 Micromet Ag Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
JP5832293B2 (ja) 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー 血管新生促進vegfイソ型を選択的に抑制する組成物および方法
PT2414322T (pt) 2009-03-20 2022-12-07 Egen Inc Derivados de poliamina
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
CN102459332B (zh) 2009-06-05 2015-08-19 埃博灵克斯股份有限公司 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
CA2770075C (en) * 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
EP2501414B1 (de) 2009-11-17 2018-01-10 The Trustees Of The University Of Pennsylvania Smn-delta-7-degron: neuartige zusammensetzungen und verfahren zu ihrer verwendung
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
PH12012501070A1 (en) 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究(慕尼黑)有限責任公司 跨物種專一性之PSMAxCD3雙專一性單鏈抗體
AU2011269260B2 (en) 2010-06-23 2015-01-15 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechtes Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
ES2657705T3 (es) 2010-06-23 2018-03-06 Deutsches Krebsforschungszentrum Secuencias de virus TT específicas y moléculas de ADN quiméricas de células hospedadoras de virus TT para uso en el diagnóstico, prevención y tratamiento del cáncer y la autoinmunidad
EP2481801A1 (de) 2011-01-28 2012-08-01 Deutsches Krebsforschungszentrum Inhibitoren von verzweigtkettiger Aminotransferase-1 (BCAT1) zur Behandlung von Neoplasie
US8951736B2 (en) 2011-04-29 2015-02-10 Sequenom, Inc. Multimer glycosylated nucleic acid binding protein conjugates and uses thereof
DK2532747T3 (en) 2011-06-09 2016-01-25 Deutsches Krebsforsch Modulators of glycerol-3-phosphate dehydrogenase (GPD2) in therapy
US20140120106A1 (en) 2011-07-06 2014-05-01 Yale University Stimulation of Arterial Collateral Growth and Lymphogenesis
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
EP2748302B1 (de) 2011-08-22 2018-08-15 Glycotope GmbH Mikroorganismen mit einem tumor-antigen
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2013113615A1 (en) 2012-02-03 2013-08-08 F. Hoffmann-La Roche Ag Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
DK2657340T3 (en) 2012-04-25 2017-02-27 Deutsches Krebsforsch Thioredoxin-interacting protein (TXNIP) inhibitors for therapy
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
ES2778033T3 (es) 2012-11-16 2020-08-07 Poseida Therapeutics Inc Enzimas específicas de sitio y métodos de uso
WO2014145205A2 (en) 2013-03-15 2014-09-18 St. Jude Children's Research Hospital Methods and compositions of p27kip1 transcription modulators
EP2808338B1 (de) 2013-09-16 2016-03-30 CeMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH Mutiertes Calreticulin zur Diagnose von Myeloidmalignitäten
CA2925281C (en) 2013-09-25 2022-05-03 Zoetis Services Llc Pcv2b divergent vaccine composition and methods of use
EP2868751A1 (de) 2013-10-30 2015-05-06 Deutsches Krebsforschungszentrum HCBI-Sequenzen als früher Marker für die zukünftige Entwicklung von Krebs und Erkrankungen des zentralen Nervensystems, und als Ziel zur Behandlung und Prävention von Krebs
EP2937096B1 (de) 2014-04-23 2019-08-21 Julius-Maximilians-Universität Würzburg Aus RS1 abgeleitete Peptide, die Glukoseabsorption nach einer glukosereichen Mahlzeit herunterregulieren und die Insulinsensitivität steigern
EP3143143A1 (de) 2014-05-15 2017-03-22 CeMM - Forschungszentrum für Molekulare Medizin GmbH Antagonisten von slc38a9 und deren verwendung in der therapie
EP2966176A1 (de) 2014-07-10 2016-01-13 Deutsches Krebsforschungszentrum HCBIO-, MSBI-, MSSI- und CMI-Sequenzen als frühe Marker für die zukünftige Entwicklung von Krebs und Erkrankungen des ZNS und als Ziel zur Behandlung und Prävention dieser Erkrankungen
EP3262064A1 (de) 2015-02-23 2018-01-03 Seagull Therapeutics SAS Nichtnatürliche semaphorine 3 und deren medizinische verwendung
JP2018521689A (ja) 2015-06-17 2018-08-09 ポセイダ セラピューティクス, インコーポレイテッド タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法
CN108137595B (zh) 2015-06-18 2021-04-20 听治疗有限责任公司 预防和治疗听力损失的方法和组合物
JP7065772B2 (ja) 2015-12-22 2022-05-12 エクスエル‐プロテイン ゲーエムベーハー 低反復性ヌクレオチド配列を有する、プロリンおよびアラニン残基が豊富な反復性アミノ酸配列をコードする核酸
EP3216458A1 (de) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modifizierter vaskulärer endothelialen wachstumsfaktor a (vegf-a) und dessen medizinische verwendung
US10036024B2 (en) 2016-06-03 2018-07-31 Purdue Research Foundation siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
EP3478722A1 (de) 2016-06-30 2019-05-08 F. Hoffmann-La Roche AG Verbesserte adoptive t-zelltherapie
CA3056837A1 (en) 2017-03-27 2018-10-04 F. Hoffmann-La Roche Ag Improved antigen binding receptors
SG11201908784TA (en) 2017-03-27 2019-10-30 Hoffmann La Roche Improved antigen binding receptor formats
EP3609519B1 (de) 2017-04-11 2025-11-26 University of Maryland, Baltimore Zusammensetzungen und verfahren zur behandlung von entzündungen und krebs
WO2019126578A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
WO2019207051A1 (en) 2018-04-25 2019-10-31 Università Degli Studi Di Torino Medical use of combinations of non-natural semaphorins 3 and antimetabolites
EP3794042B1 (de) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Conjugue agent cytotoxique et anticorps anti-muc1-exatecan
EP3686289A1 (de) 2019-01-24 2020-07-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Cmi-sequenzen als frühmarker für die zukünftige entwicklung von krebs, atherosklerose, diabetes und erkrankungen des zns und als ziel für die behandlung und prävention dieser erkrankungen
WO2022029051A1 (en) 2020-08-03 2022-02-10 F. Hoffmann-La Roche Ag Improved antigen binding receptors
AR124562A1 (es) 2020-10-28 2023-04-12 Hoffmann La Roche Receptores de unión al antígeno mejorada
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
US20250325469A1 (en) 2021-01-24 2025-10-23 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses
JP2024528631A (ja) 2021-07-22 2024-07-30 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト ヘテロ二量体Fcドメイン抗体
CA3237616A1 (en) 2021-11-25 2023-06-01 F. Hoffmann-La Roche Ag Improved antigen binding receptors
JP2025512797A (ja) 2022-03-25 2025-04-22 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 改善されたキメラ受容体
AR129560A1 (es) 2022-06-08 2024-09-04 Tidal Therapeutics Inc Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
JP7880106B2 (ja) 2022-08-09 2026-06-25 湖南長星生物医藥有限公司 金属-ポリフェノール複合体粒子、薬物-脂質粒子、並びにその製造方法及び応用
IL318505A (en) 2022-08-09 2025-03-01 Hunan Lonstar Biotech Co Ltd Metal-phospholipid complex, metal-phospholipid complex particle, drug-lipid particle, method for preparing same, and use thereof
TWI872406B (zh) * 2022-12-07 2025-02-11 日商都滾筒工業股份有限公司 有孔搬送輥、片材製造裝置及片材加工裝置
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof
WO2026072557A2 (en) 2024-09-24 2026-04-02 Genzyme Corporation Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2026112559A1 (en) 2024-11-25 2026-05-28 Genzyme Corporation Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0591408A4 (en) * 1991-06-28 1996-11-27 Univ Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor

Also Published As

Publication number Publication date
DE69434447D1 (de) 2005-09-08
EP0702722A1 (de) 1996-03-27
US5910488A (en) 1999-06-08
CA2164088C (en) 2005-06-14
EP0702722B1 (de) 2005-08-03
WO1994029469A2 (en) 1994-12-22
CA2164088A1 (en) 1994-12-22
JP3626187B2 (ja) 2005-03-02
DE69434447T2 (de) 2006-05-18
JPH08510911A (ja) 1996-11-19
WO1994029469A3 (en) 1995-03-23

Similar Documents

Publication Publication Date Title
DE69434447D1 (de) Für die gentherapie verwendbare plasmide
AU6787894A (en) Adenoviral vectors of animal origin and use in gene therapy
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
DE69636032D1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
DE69434808D1 (de) Adenoviren mit veränderten faserproteinen
ATE319827T1 (de) Polypeptid, das die differenzierung unterdrueckt
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
HUT73215A (en) Recombinant adenoviruses and use thereof in gene therapy
EP0744408A3 (de) Das ob Protein der Rhesusaffen und seine DNA
HU9401604D0 (en) Production of proteins using fb2 protein
AP2000001999A0 (en) Gene therapy method.
AU5810498A (en) Method and constructs for inhibiting protein expression in bacteria
ATE226094T1 (de) Verfahren zur arzneistoffabgabe mittels gentherapie
MXPA05004973A (es) Agentes para aliviar el dolor.
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
GB2249312B (en) Cell growth inhibitors
AU4037299A (en) Genetically-modified fibroblasts and the use thereof
CA2139430A1 (fr) Polypeptides ayant une activite de recepteur serotoninergique (5ht5a), acides nucleiques codant pour ces polypeptides et utilisations
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
WO1995006744A3 (en) Methods of suppressing immune response by gene therapy
DE69434072D1 (de) Regulierende nukleinsaeuresequenzen und verwendungen
GB2333527A (en) Therapeutic gene
NZ336371A (en) Human gene therapy using DNA/RNA cassette expression systems
CA2278223A1 (fr) Derives de la 1,4-dihydropyridine et leur utilisation en therapeutique

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties